Ann: AVITA Medical Expands Portfolio with Unique Dermal Matrix, page-43

Thanks for the excellent post Salty. I admit the argument for the Revenity deal is compelling. But I can't ignore a 3M drop in revenue without any real explanation. Had JC said the evidence showed accounts were holding back orders waiting for GO that and the lower burn admits in Jan. would have explained. But he clearly stated he had studied the issue and found no evidence accounts were holding back. And if lower burn admissions in Feb. and March were the cause, that's a trend, not a fluke.
I may take a nibble based on what I consider a step forward with the new VP. But I need to see Q2 numbers first. Even if they make high end of estimate and manage 40% Q over Q growth in Q3 and Q4, phenomenal achievement, they would still be 2M shy of low end YE estimate.
There has been a lot of money spent and around 40M guaranteed outlay to partners over next 5 years on products with no sales history. No problem IF it all goes as planned.
Some here may not believe it, but I really do appreciate the greatness of the product here. Have felt that way since I stumbled across it almost 7 years ago. But as I've said, it's a business, and there are things on the business side that at least have the potential of turning into train wreck.
I hate being a negative Nancy (apologies to all Nancys) and have major heartburn from whytee agreeing with me. But got to sit tight. Best to you and yours. Think your cape will serve you well now and in the future. I do homework, you do thesis research.